The proof of principle that a drug targeting mTOR can improve survival has been obtained recently from a large randomised trial using temsirolimus as a first-line therapy in patients with advanced poor prognostic renal cell carcinoma. The gene discussed is MTOR; the disease is hereditary clear cell renal cell carcinoma.